[go: up one dir, main page]

BRPI0408006A - uso de ácidos graxos Èmega -3 no tratamento de pacientes diabéticos - Google Patents

uso de ácidos graxos Èmega -3 no tratamento de pacientes diabéticos

Info

Publication number
BRPI0408006A
BRPI0408006A BRPI0408006-8A BRPI0408006A BRPI0408006A BR PI0408006 A BRPI0408006 A BR PI0408006A BR PI0408006 A BRPI0408006 A BR PI0408006A BR PI0408006 A BRPI0408006 A BR PI0408006A
Authority
BR
Brazil
Prior art keywords
fatty acids
omega
treatment
diabetic patients
ethyl ester
Prior art date
Application number
BRPI0408006-8A
Other languages
English (en)
Inventor
Rainer Oelze
Cees-Nico Verboom
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of BRPI0408006A publication Critical patent/BRPI0408006A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USO DE áCIDOS GRAXOS ÈMEGA -3 NO TRATAMENTO DE PACIENTES DIABéTICOS". A presente invenção refere-se ao uso de ácidos graxos essenciais com um alto teor de éster de etila de ácido eicosapentenóico (EPA) ou de éster de etila de ácido docosahexaenóico (DHA) útil para evitar eventos cardiovasculares em pacientes com diabetes melito.
BRPI0408006-8A 2003-03-05 2004-03-02 uso de ácidos graxos Èmega -3 no tratamento de pacientes diabéticos BRPI0408006A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03004792 2003-03-05
PCT/EP2004/050238 WO2004078166A2 (en) 2003-03-05 2004-03-02 Use of omega-3-fatty acids in the treatment of diabetic patients

Publications (1)

Publication Number Publication Date
BRPI0408006A true BRPI0408006A (pt) 2006-02-14

Family

ID=32946844

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408006-8A BRPI0408006A (pt) 2003-03-05 2004-03-02 uso de ácidos graxos Èmega -3 no tratamento de pacientes diabéticos

Country Status (8)

Country Link
EP (1) EP1603551A2 (pt)
JP (1) JP2006519244A (pt)
CN (1) CN1756545A (pt)
AU (1) AU2004216856A1 (pt)
BR (1) BRPI0408006A (pt)
CA (1) CA2515328A1 (pt)
MX (1) MXPA05009432A (pt)
WO (1) WO2004078166A2 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
CA2593768C (en) 2005-01-04 2014-02-18 Mochida Pharmaceutical Co., Ltd. Use of .omega.3 unsaturated fatty acids for relieving lipotoxicity
CN101213281B (zh) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
RU2441061C2 (ru) * 2005-05-04 2012-01-27 Пронова Биофарма Норге Эс. Производные докозагексаеновой кислоты и их применение в качестве лекарственных средств
JP2008540394A (ja) * 2005-05-04 2008-11-20 プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用
KR101255650B1 (ko) * 2005-05-04 2013-04-16 프로노바 바이오파마 너지 에이에스 새로운 ｄｈａ 유도체 및 약제로서의 용도
JP5134916B2 (ja) * 2005-07-08 2013-01-30 持田製薬株式会社 心血管イベント発症予防用組成物
ES2489741T3 (es) * 2005-07-08 2014-09-02 Mochida Pharmaceutical Co., Ltd. Composición para la prevención de la aparición de acontecimientos cardiovasculares
RU2507193C2 (ru) * 2006-11-01 2014-02-20 Пронова Биофарма Норге А/С Альфа-замещенные омега-3 липиды, которые являются активаторами или модуляторами рецептора, активируемого пролифераторами пероксисом (ppar)
EP2102139A2 (en) * 2006-11-01 2009-09-23 Pronova Biopharma Norge AS Omega-3 lipid compounds
MX2009004336A (es) * 2006-11-01 2009-05-22 Pronova Biopharma Norge As Lipidos omega-3 alfa-sustituidos que son activadores o moduladores del receptor activado por proliferadores de peroxisoma (ppar).
CA2667153A1 (en) * 2006-11-03 2008-11-20 Pronova Biopharma Norge As Fatty acid alcohols
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
EP4137128A1 (en) 2008-09-02 2023-02-22 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same
NZ594395A (en) 2009-02-10 2014-01-31 Amarin Pharmaceuticals Ie Ltd Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
US20120100208A1 (en) 2009-04-29 2012-04-26 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
US20120093922A1 (en) 2009-04-29 2012-04-19 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SG177254A1 (en) 2009-06-15 2012-02-28 Ian Osterloh Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
CN104814950A (zh) * 2010-11-09 2015-08-05 持田制药株式会社 血糖值上升抑制剂在制造经口摄取用食品中的应用
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
PT4342546T (pt) 2012-06-29 2025-09-01 Amarin Pharmaceuticals Ie Ltd Éster etílico do ácido eicosapentanoico para utilização na redução do risco de acidente vascular cerebral não-fatal num indivíduo em terapia com estatina
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
DK4056176T3 (da) 2018-09-24 2024-05-06 Amarin Pharmaceuticals Ie Ltd Fremgangsmåde til at reducere risikoen af kardiovaskulære hændelser hos et individ
US12427134B2 (en) 2019-11-12 2025-09-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60248610A (ja) * 1984-05-23 1985-12-09 Nitsusui Seiyaku Kk 糖尿病合併症の予防および治療剤
GB2218904A (en) * 1988-05-27 1989-11-29 Renafield Limited Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
GB2223943A (en) * 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids

Also Published As

Publication number Publication date
MXPA05009432A (es) 2005-11-23
CA2515328A1 (en) 2004-09-16
AU2004216856A1 (en) 2004-09-16
EP1603551A2 (en) 2005-12-14
CN1756545A (zh) 2006-04-05
WO2004078166A3 (en) 2004-10-28
WO2004078166A2 (en) 2004-09-16
JP2006519244A (ja) 2006-08-24

Similar Documents

Publication Publication Date Title
BRPI0408006A (pt) uso de ácidos graxos Èmega -3 no tratamento de pacientes diabéticos
BR0008153A (pt) Uso de ácidos graxos essenciais na prevenção de eventos cardiovasculares
WO2007070611A3 (en) Nutritional supplement containing long-chain polyunsaturated fatty acids
PT1310249E (pt) Utilizacao de acidos gordos poli-insaturados para prevencao primaria de eventos cardiovasculares graves
BRPI0418921A (pt) uso de ácidos graxos poliinsaturados, composição nutricional, e, uso de uma composição
WO2008018043A3 (en) Methods of improving bone health and muscle health
DE69622722D1 (de) Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselssyndroms
WO2005089744A3 (en) Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
KR940018090A (ko) 트리글리세라이드
CO6470839A2 (es) Composiciones farmacéuticas que contienen epa y un agente cardiovascular y métodos de emplearlas
DE60330154D1 (de) Resolvine: biotemplate zur durchführung therapeutischer anwendungen
BR0112073A (pt) Combinações terapêuticas de ácidos graxos
MXPA05003346A (es) Control glicemico mejorado para prediabetes y/o diabetes tipo ii utilizando acido docosahexaenoico.
DE602005021668D1 (de) Pharmazeutische formulierung mit statinmikrokapseln in alkylestern mehrfach ungesättigter fettsäuren
WO2008036353A3 (en) Omega-3 diglyceride emulsions
MX2010004820A (es) Mezcla lipidica para nutricion infantil.
NZ599748A (en) Improving memory in subjects with mini-mental state examination of 24-26
EP1698685A4 (en) FAT COMPOSITION
CO6150156A2 (es) Esteres de dha y su utilizacion en el tratamiento y la prevencion de enfermedades cardiovasculares
BRPI0517479A (pt) nutrição contendo mistura de gorduras
BRPI0512528A (pt) uso de ácidos graxos poliinsaturados, composição nutricional, e, uso de uma composição
EP1765324A4 (en) COMPOSITIONS BASED ON STABLE BIOACTIVE METABOLITES OF DOCOSAHEXANOIC (DHA) AND EICOSAPENTANOIC ACIDS (EPA)
Hiratsuka et al. Effect of dietary docosahexaenoic acid connecting phospholipids on the lipid peroxidation of the brain in mice
WO2006111633A3 (fr) Utilisation de la lecithine comme medicament dans le traitement du psoriasis
WO2002092779A3 (en) Method for enriching tissues in long chain polyunsaturated fatty acids

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired